Drug Profile
Research programme: insulin phosphatase inhibitors - SUGEN
Alternative Names: Insulin phosphatase inhibitors research programme - SUGENLatest Information Update: 29 Feb 2008
Price :
$50
*
At a glance
- Originator SUGEN
- Class Small molecules
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
- 26 Jan 1999 Preclinical development for Type-1 diabetes mellitus in USA (Unknown route)